[Prolonged treatment with slow release nicotinic acid in patients with type II hyperlipidemia]

The aim of the study was to compare efficacy and safety of one-year therapy with slow-release nicotinic acid (KN-SR) and with ordinary form of the acid (KN). The examination was performed in the group of 136 patients with hyperlipidemia-type II. KN-SR had satisfactory effectiveness and was much better tolerated than KN. During one-year treatment with KN-SR there were observed the decrease of total cholesterol (TC) by 18%, LDL-C by 22%, triglycerides by 36%, Lp(a) by 56%, and the increase of HDL-C by 12%. The percentage of skin unwanted signs differed significantly between KN-group (90.2%) and KN-SR group (24%). Hepatotoxic effects were not observed and antipyrine kinetics did not change during one-year treatment with slow-release nicotinic acid.